Memo Therapeutics

Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis.

Its MemoMAB™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’s immune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery.

MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations.

Memo Therapeutics headquartered in Switzerland, Europe, operates in the Collaboration, Biotechnology sector. The company focuses on Collaboration and has secured $6.1B in funding across 56 round(s). With a team of 11-50 employees, Memo Therapeutics is actively contributing to advancements in Collaboration. Their latest funding round, Series A - Memo Therapeutics, raised $2.3M. Discover more about their projects, partnerships, and impact on our platform.